“…A variety of functional groups that either occur naturally or have been specifically engineered into drugs to increase their stability, solubility, or bioavailability have been shown to predispose these drugs to metabolism by a particular P450 isozyme or isozymes in such a way as to generate reactive intermediates that can lead to MBI by one or more of the previously mentioned routes These molecules can be grouped according to their structural aspects and they fall into a number of major categories including: (a) various sulfur-containing compounds (eg, carbon disulfide [281][282][283], diethyldithiocarbamate [284], isothiocyanates [285], mercaptosteroids [286][287][288][289][290][291][292][293], parathion [294,295], thioureas [296], thiophenes [297], and tienilic acid [298]; (b) various halogen containing compounds such as chloramphenicol [299][300][301][302], N-monosubstituted dichloroacetamides [303], and N(2-p-nitrophenethyl) dichloroacetamide [304]; (c) acetylenes and alkyl and aryl olefins [305][306][307][308][309][310][311] [328][329][330][331][332][333][334][335][336], and the furanopyridine, L-75...…”